| 4.15 Data as of May 22 |  +0.08 / +1.97%Today’s Change | 3.21 Today|||52-Week Range 11.30 | -14.43% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $545.2M |
Idenix Pharmaceuticals, Inc. 60 Hampshire Street Cambridge Massachusetts 02139-1548 |
| Other institutional | 45.36% |
| Individual stakeholders | 35.51% |
| Mutual fund holders | 27.47% |
| Ronald C. Renaud, Jr., MBA | President, Chief Executive Officer & Director |
| Daniella Beckman, CPA | Chief Financial Officer, Treasurer & Senior VP |
| Douglas L. Mayers, MD | Chief Medical Officer & EVP-Clinical Development |
| David N. Standring, PhD | Chief Scientific Officer & Executive VP |
| John Z. Sullivan-Bólyai, MD | Vice President-Clinical Research |
.
